The human body is an amazing physiological machine. The old adage, “you are what you eat,” has proven time and again to be true, as our body takes what we ingest and turns it into energy and nutrients, while protecting us against harmful bacteria and supporting our nervous system.
There is increasing evidence that our body’s gut microbiota - bacteria, fungus, and other intestinal microbes - have a beneficial symbiotic relationship to support our metabolism and regulate inflammation in not only the gut but in...
The human body is an amazing physiological machine. The old adage, “you are what you eat,” has proven time and again to be true, as our body takes what we ingest and turns it into energy and nutrients, while protecting us against harmful bacteria and supporting our nervous system.
There is increasing evidence that our body’s gut microbiota - bacteria, fungus, and other intestinal microbes - have a beneficial symbiotic relationship to support our metabolism and regulate inflammation in not only the gut but in other organs such as the brain. When the human body undergoes alterations in gut health due to factors such as stress, nutrition, environmental factors, and pharmaceuticals, it responds through the gut by changing the body’s metabolism as it increases its inflammatory response. These changes also affect our immune health, as chronic inflammation can trigger depletion of immune cells, increasing the risk of infection.
In this episode of Cannabis Nurse Truths, we consider the major role that the endocannabinoid system plays in not only digestive health but also in maintaining homeostasis by interacting with the gut microbiota. In other words, we need a healthy endocannabinoid system to maintain gut health, and research has indicated that cannabinoids, such as THC and CBD, are major players in regulating the gut microbiome itself. It seems that individuals who use cannabis are also supporting their gut health as it protects against both inflammatory and immune disorders as well as helping to repair damage done by these conditions.
EPISODE RESOURCES
Ahmed, W., & Katz, S. (2016). Therapeutic use of cannabis in inflammatory bowel disease. Gastroenterology & Hepatology, 12(11), 668–679. https://pubmed.ncbi.nlm.nih.gov/28035196/
Al-Khazaleh, A.K., Jaye, K., Chang, D., Münch, G.W., & Bhuyan, D.J. (2024). Buds and bugs: A fascinating tale of gut microbiota and cannabis in the fight against cancer. International Journal of Molecular Sciences, 25(2), 872. https://doi.org/10.3390/ijms25020872
Barbash, B., Mehta, D., Siddiqui, M., Chawla, L., & Dworkin, B. (2019). Impact of cannabinoids on symptoms of refractory gastroparesis: A single-center experience. Cureus, 11(12). https://www.cureus.com/articles/25832-impact-of-cannabinoids-on-symptoms-of-refractory-gastroparesis-a-single-center-experience
Boehm, E., Droessler, L., & Amasheh, S. (2023). Cannabidiol attenuates inflammatory impairment of intestinal cells expanding biomaterial-based therapeutic approaches. Materials Today Bio, 23, 100808. https://doi.org/10.1016/j.mtbio.2023.100808
Borra, V., Borra, N., Bondi, G., Yartha, S.G.R., Machineni, N.V., Agarwal, C., Ramasahayam, K., Kuchipudi, P.R., Mundla, S.R., Bansal, P., Bathija, S.A., Ogbu, I.R., & Desai, R. (2024). Is dependent cannabis use in adult hospitalizations with inflammatory bowel disease associated with major adverse cardiovascular and cerebrovascular events? Insights from National Inpatient Sample Analysis. Current Medical Research and Opinion, 1–7. https://doi.org/10.1080/03007995.2024.2321328
Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., Orlando, P., Battista, G., Pagano, E., Di Marzo, V., & Izzo, A.A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306–1316. https://doi.org/10.1016/j.bcp.2013.01.017
Brown, K., Funk, K., Figueroa Barrientos, A., Bailey, A., Shrader, S., Feng, W., McClain, C. J., & Song, Z.-H. (2024). The modulatory effects and therapeutic potential of cannabidiol in the gut. Cells, 13(19), 1618. https://doi.org/10.3390/cells13191618
Camilleri, M. (2018). Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterology & Motility, 30(9), e13370. https://doi.org/10.1111/nmo.13370
Cani, P.D., Plovier, H., Van Hul, M., Geurts, L., Delzenne, N.M., Druart, C., & Everard, A. (2016). Endocannabinoids—At the crossroads between the gut microbiota and host metabolism. Nature Reviews Endocrinology, 12(3), 133–143. https://doi.org/10.1038/nrendo.2015.211
Cohen, G., Gover, O., & Schwartz, B. (2023). Phytocannabinoids reduce inflammation of primed macrophages and enteric glial cells: An in vitro study. International Journal of Molecular Sciences, 24(19), Article 19. https://doi.org/10.3390/ijms241914628
Couch, D.G., Maudslay, H., Doleman, B., Lund, J.N., & O’Sullivan, S.E. (2018). The use of cannabinoids in colitis: A systematic review and meta-analysis. Inflammatory Bowel Diseases, 24(4), 680–697. https://doi.org/10.1093/ibd/izy014
Dalavaye, N., Erridge, S., Nicholas, M., Pillai, M., Bapir, L., Holvey, C., Coomber, R., Rucker, J.J., Hoare, J., & Sodergren, M.H. (2023). The effect of medical cannabis in inflammatory bowel disease: Analysis from the UK Medical Cannabis Registry. Expert Review of Gastroenterology & Hepatology, 17(1), 85–98. https://doi.org/10.1080/17474124.2022.2161046
De Filippis, D., Esposito, G., Cirillo, C., Cipriano, M., De Winter, B.Y., Scuderi, C., Sarnelli, G., Cuomo, R., Steardo, L., De Man, J.G., & Iuvone, T. (2011). Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS ONE, 6(12). https://doi.org/10.1371/journal.pone.0028159
Hasenoehrl, C., Taschler, U., Storr, M., & Schicho, R. (2016). The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease. Neurogastroenterology and Motility : The Official Journal of the European Gastrointestinal Motility Society, 28(12), 1765–1780. https://doi.org/10.1111/nmo.12931
Kafil, T.S., Nguyen, T.M., MacDonald, J.K., & Chande, N. (2020). Cannabis for the treatment of Crohn’s disease and ulcerative colitis: Evidence from Cochrane Reviews. Inflammatory Bowel Diseases, 26(4), 502–509. https://doi.org/10.1093/ibd/izz233
Karoly, H.C., Mueller, R.L., Bidwell, L.C., & Hutchison, K.E. (2020). Cannabinoids and the microbiota-gut-brain axis: Emerging effects of cannabidiol and potential applications to alcohol use disorders. Alcoholism, Clinical and Experimental Research, 44(2), 340–353. https://doi.org/10.1111/acer.14256
Lahat, A., Lang, A., & Ben-Horin, S. (2012). Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: A pilot prospective study. Digestion, 85(1), 1–8. https://doi.org/10.1159/000332079
Lal, S., Prasad, N., Ryan, M., Tangri, S., Silverberg, M.S., Gordon, A., & Steinhart, H. (2011). Cannabis use amongst patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology, 23(10), 891–896. https://doi.org/10.1097/MEG.0b013e328349bb4c
Langat, R., Chakrawarti, A., & Klatt, N.R. (2025). Cannabis use in HIV: Impact on inflammation, immunity and the microbiome. Current HIV/AIDS Reports, 22(1), 19. https://doi.org/10.1007/s11904-025-00729-0
Lee, Y., Jo, J., Chung, H.Y., Pothoulakis, C., & Im, E. (2016). Endocannabinoids in the gastrointestinal tract. American Journal of Physiology. Gastrointestinal and Liver Physiology, 311(4), G655–G666. https://doi.org/10.1152/ajpgi.00294.2015
Leinwand, K.L., Jones, A.A., Huang, R.H., Jedlicka, P., Kao, D.J., de Zoeten, E.F., Ghosh, S., Moaddel, R., Wehkamp, J., Ostaff, M.J., Bader, J., Aherne, C.M., & Collins, C.B. (2017). Cannabinoid receptor-2 ameliorates inflammation in murine model of Crohn’s Disease. Journal of Crohn’s & Colitis, 11(11), 1369–1380. https://doi.org/10.1093/ecco-jcc/jjx096
Lo, B.D., Chen, S.Y., Stem, M., Papanikolaou, A., Gabre-Kidan, A., Safar, B., Efron, J.E., & Atallah, C. (2024). Prevalence of cannabis use disorder and perioperative outcomes in adult colectomy patients: A propensity score-matched analysis. World Journal of Surgery, 48(3), 701–712. https://doi.org/10.1002/wjs.12085
Martin, C.R., Osadchiy, V., Kalani, A., & Mayer, E.A. (2018). The brain-gut-microbiome axis. Cellular and Molecular Gastroenterology and Hepatology, 6(2), 133–148. https://doi.org/10.1016/j.jcmgh.2018.04.003
Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E.P., Sklerovsky Benjaminov, F., & Konikoff, F.M. (2013). Cannabis induces a clinical response in patients with Crohn’s Disease: A prospective placebo-controlled study. Clinical Gastroenterology and Hepatology, 11(10), 1276-1280.e1. https://doi.org/10.1016/j.cgh.2013.04.034
Naftali, T., Lev, L.B., Yablecovitch, D., Yablekovitz, D., Half, E., & Konikoff, F.M. (2011). Treatment of Crohn’s disease with cannabis: An observational study. The Israel Medical Association Journal: IMAJ, 13(8), 455–458. https://pubmed.ncbi.nlm.nih.gov/21910367/
Naftali, T., Mechulam, R., Lev, L.B., & Konikoff, F.M. (2014). Cannabis for inflammatory bowel disease. Digestive Diseases, 32(4), 468–474. https://doi.org/10.1159/000358155
Rossi, G., Gioacchini, G., Pengo, G., Suchodolski, J.S., Jergens, A.E., Allenspach, K., Gavazza, A., Scarpona, S., Berardi, S., Galosi, L., Bassotti, G., & Cerquetella, M. (2020). Enterocolic increase of cannabinoid receptor type 1 and type 2 and clinical improvement after probiotic administration in dogs with chronic signs of colonic dysmotility without mucosal inflammatory changes. Neurogastroenterology & Motility, 32(1). https://doi.org/10.1111/nmo.13717
Uranga, J.A., Vera, G., & Abalo, R. (2018a). Cannabinoid pharmacology and therapy in gut disorders. Biochemical Pharmacology, 157, 134–147. https://doi.org/10.1016/j.bcp.2018.07.048
Uranga, J.A., Vera, G., & Abalo, R. (2018b). Cannabinoid pharmacology and therapy in gut disorders. Biochemical Pharmacology, 157, 134–147. https://doi.org/10.1016/j.bcp.2018.07.048
Varsha, K.K., Nagarkatti, M., & Nagarkatti, P. (2022). Role of gut microbiota in cannabinoid-mediated suppression of inflammation. Advances in Drug and Alcohol Research, 2, 10550. https://doi.org/10.3389/adar.2022.10550
Velez-Santiago, A., Alvarez-Torres, E., Martinez-Rodriguez, R., Candal-Rivera, E., Muniz-Camacho, L., Ramos-Burgos, L., & Torres, E. A. (2023). A survey of cannabis use among patients with inflammatory bowel disease (IBD). International Journal of Environmental Research and Public Health, 20(6), 5129. https://doi.org/10.3390/ijerph20065129
Zhang, X., Gao, X., Yi, X., Yu, H., Shao, M., Li, Y., & Shen, X. (2024). Multi-targeting inulin-based nanoparticles with cannabidiol for effective prevention of ulcerative colitis. Materials Today Bio, 25, 100965. https://doi.org/10.1016/j.mtbio.2024.100965
